- Aimedbio's candidate of 'P018' has been selected as a "novel therapeutics-based expansion research" project by the Korean Drug Development Project (KDDF) and will receive research funds to derive its lead over the next two years.
- P018 is an antibody targeting the tumor microenvironment (TME) which activates immune cells such as T cells and NK cells by removing tumor-associated macrophages (TAM).
- Aimedbio expects to solve unmet medical needs in solid cancers such as brain tumors and lung cancer through combination of P018 and immuno-oncology drugs.
Link to full news: http://www.biospectator.com/view/news_view.php?varAtcId=17637